HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026

Executive Summary

Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.

You may also be interested in...



Euro Q1 Consumer Health Earnings Preview: Sanofi, Reckitt, GSK And Bayer

Major Europe-based consumer health players Sanofi, Reckitt, GSK and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2022 results over the coming weeks.

Poland’s Adamed Secures Tadalafil Rx-To-OTC Switch In World First

Poland becomes the first country in the world to allow erectile dysfunction treatment tadalafil to be bought without a prescription thanks to a successful Rx-to-OTC switch application from local player Adamed Pharma.

Sanofi Not Distracted By M&A Chatter As It Gets Back On Par With Market Growth

Recent market interest shown in other OTC assets will not distract Sanofi from its long-term plan to overhaul its Consumer Healthcare business, says CEO Paul Hudson. And this plan is delivering results, with Sanofi back on par with the consumer health market, posting sales up by 5% in 2021.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel